Founders

Max Krummel, PhD

Robert E. Smith Endowed Chair in Experimental Pathology, UCSF

Dr. Krummel is a Professor and the Robert E. Smith Endowed Chair in Experimental Pathology at UCSF. He studies mechanisms that regulate T cell response and immune function, using cutting-edge real-time imaging methods. As a graduate student, he developed expertise in the generation and use of monoclonal antibodies targeted to costimulatory and inhibitory molecules on T cells. He generated antibodies to CTLA-4, which identified an inhibitory pathway of T cell regulation and also could be used to trigger or block that pathway. This approach led to the development of human antibodies of the same type, a therapy now named ‘ipilimumab’, now FDA approved and widely used for treatment of melanoma and other cancers.

Dr. Krummel’s lab now focuses on figuring out how immune systems, collections of cells in complex tissues, work. The use of fluorescent proteins and real-time imaging enable the examination of information processing by the immune system. These approaches reveal how motile immune cells ‘search’ their environment for critical information and characterize specific phagocytes in the tumor microenvironments as primary players in transmitting signals to lymphocytes and regulating disease outcome.

Dr. Krummel earned his doctorate at UC Berkeley and did postdoctoral fellowships at Stanford University and the Walter and Eliza Hall Institute in Melbourne, Australia.

Sachdev Sidhu

Professor, University of Toronto

Dr. Sidhu is an expert in phage display technology and structure-based and combinatorial protein engineering. Prior to joining the University of Toronto in April 2008, he spent a decade as a principal investigator in the Department of Protein Engineering at Genentech, Inc., where he led the development of phage-displayed synthetic antibody libraries that have since proven to be a rich source of valuable reagents for basic research and potential therapeutics. His University of Toronto laboratory houses the TRAC (Toronto Recombinant Antibody Centre), an integrated laboratory with a state-of-theĀ­art, high throughput antibody research platform that can be applied to the generation of therapeutic-grade antibodies. Recently, Dr. Sidhu has launched the Centre for the Commercialization of Antibodies and Biologics (CCAB), a Government of Canada-sponsored Centre of Excellence, that functions as a bridge between academic discoveries and their industrial production and marketing.